Brian Cheng
Stock Analyst at JP Morgan
(1.23)
# 2,560
Out of 4,412 analysts
50
Total ratings
37.84%
Success rate
-15.64%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Downgrades: Underweight | n/a | $1.41 | - | 2 | Mar 22, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Neutral | $5 | $2.94 | +70.07% | 3 | Mar 19, 2024 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $29 → $27 | $10.80 | +150.00% | 1 | Mar 12, 2024 | |
| MGX Metagenomi | Initiates: Overweight | $16 | $7.53 | +112.48% | 1 | Mar 5, 2024 | |
| AHR American Healthcare REIT | Initiates: Outperform | $15 | $13.68 | +9.65% | 1 | Mar 4, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $39 | $15.47 | +152.10% | 1 | Mar 4, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $34 → $37 | $25.15 | +47.12% | 2 | Feb 28, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $8 | $2.89 | +176.82% | 3 | Feb 27, 2024 | |
| EDIT Editas Medicine | Maintains: Neutral | $8 → $9 | $5.32 | +69.17% | 2 | Feb 27, 2024 | |
| IMVT Immunovant | Initiates: Overweight | $51 | $27.17 | +87.71% | 1 | Feb 20, 2024 | |
| CRGX CARGO Therapeutics | Initiates: Overweight | $23 | $18.68 | +23.13% | 1 | Dec 5, 2023 | |
| ROIV Roivant Sciences | Maintains: Overweight | $16 → $15 | $11.03 | +35.99% | 6 | Nov 14, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $44 → $46 | $49.86 | -7.74% | 4 | Oct 12, 2023 | |
| BCAB BioAtla | Maintains: Overweight | $17 → $14 | $2.54 | +451.18% | 3 | Sep 25, 2023 | |
| ADCT ADC Therapeutics | Upgrades: Neutral | n/a | $4.34 | - | 3 | Aug 10, 2023 | |
| ACET Adicet Bio | Downgrades: Neutral | $20 → $6 | $1.68 | +257.14% | 2 | Jun 1, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $82 → $79 | $20.76 | +280.54% | 2 | Mar 31, 2023 | |
| ZYME Zymeworks | Maintains: Neutral | $8 → $9 | $8.26 | +8.96% | 1 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Overweight | $37 → $42 | $19.98 | +110.21% | 2 | Feb 13, 2023 | |
| SNTI Senti Biosciences | Initiates: Neutral | n/a | $0.29 | - | 1 | Dec 16, 2022 | |
| GOSS Gossamer Bio | Downgrades: Underweight | n/a | $0.67 | - | 2 | Dec 7, 2022 | |
| PSTX Poseida Therapeutics | Initiates: Overweight | $24 | $2.13 | +1,026.76% | 1 | Jan 7, 2022 | |
| IMNM Immunome | Initiates: Overweight | n/a | $13.73 | - | 1 | Oct 29, 2021 | |
| RGLS Regulus Therapeutics | Initiates: Overweight | n/a | $2.42 | - | 1 | Sep 2, 2021 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | n/a | $26.55 | - | 2 | Aug 10, 2021 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | n/a | $4.16 | - | 1 | Aug 3, 2021 |
Precigen
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.41
Upside: -
Mersana Therapeutics
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $2.94
Upside: +70.07%
iTeos Therapeutics
Mar 12, 2024
Maintains: Overweight
Price Target: $29 → $27
Current: $10.80
Upside: +150.00%
Metagenomi
Mar 5, 2024
Initiates: Overweight
Price Target: $16
Current: $7.53
Upside: +112.48%
American Healthcare REIT
Mar 4, 2024
Initiates: Outperform
Price Target: $15
Current: $13.68
Upside: +9.65%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $39
Current: $15.47
Upside: +152.10%
Protagonist Therapeutics
Feb 28, 2024
Maintains: Overweight
Price Target: $34 → $37
Current: $25.15
Upside: +47.12%
Allogene Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $2.89
Upside: +176.82%
Editas Medicine
Feb 27, 2024
Maintains: Neutral
Price Target: $8 → $9
Current: $5.32
Upside: +69.17%
Immunovant
Feb 20, 2024
Initiates: Overweight
Price Target: $51
Current: $27.17
Upside: +87.71%
CARGO Therapeutics
Dec 5, 2023
Initiates: Overweight
Price Target: $23
Current: $18.68
Upside: +23.13%
Roivant Sciences
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.03
Upside: +35.99%
Apellis Pharmaceuticals
Oct 12, 2023
Maintains: Neutral
Price Target: $44 → $46
Current: $49.86
Upside: -7.74%
BioAtla
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $2.54
Upside: +451.18%
ADC Therapeutics
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.34
Upside: -
Adicet Bio
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $1.68
Upside: +257.14%
Intellia Therapeutics
Mar 31, 2023
Maintains: Overweight
Price Target: $82 → $79
Current: $20.76
Upside: +280.54%
Zymeworks
Mar 31, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $8.26
Upside: +8.96%
Xencor
Feb 13, 2023
Maintains: Overweight
Price Target: $37 → $42
Current: $19.98
Upside: +110.21%
Senti Biosciences
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.29
Upside: -
Gossamer Bio
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.67
Upside: -
Poseida Therapeutics
Jan 7, 2022
Initiates: Overweight
Price Target: $24
Current: $2.13
Upside: +1,026.76%
Immunome
Oct 29, 2021
Initiates: Overweight
Price Target: n/a
Current: $13.73
Upside: -
Regulus Therapeutics
Sep 2, 2021
Initiates: Overweight
Price Target: n/a
Current: $2.42
Upside: -
Arcturus Therapeutics Holdings
Aug 10, 2021
Maintains: Overweight
Price Target: n/a
Current: $26.55
Upside: -
BioCryst Pharmaceuticals
Aug 3, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.16
Upside: -